Uncategorized

New Article on Antidepressive Effects with NeuroRestore ACD856

AlzeCure Pharma AB a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that a new scientific article on preclinical results supporting antidepressive effects with NeuroRestore ACD856 has been published.

New Article on Antidepressive Effects with NeuroRestore ACD856 Read More »

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

Sosei Group Corporation announces it has dosed the first subject in a Phase I trial evaluating HTL0048149, a first-in-class GPR52 agonist, which represents a novel mechanism of action for the treatment of schizophrenia and related neurological diseases.

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia Read More »

Lifera and CENTOGENE, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

CENTOGENE N.V. and Lifera have announced a strategic collaboration with the formation of a Joint Venture to increase local and regional access and rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council.

Lifera and CENTOGENE, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing Read More »

Scroll to Top